Literature DB >> 21068103

Statin therapy in lupus-mediated atherogenesis: two birds with one stone?

Sander I van Leuven1, Yanice V Mendez-Fernandez, Erik S Stroes, Paul P Tak, Amy S Major.   

Abstract

The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21068103      PMCID： PMC3306212          DOI： 10.1136/ard.2010.133827

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  28 in total

Review 1.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 2.  Atherogenesis in rheumatology.

Authors:  S I van Leuven; J J P Kastelein; D P D'Cruz; G R Hughes; E S Stroes
Journal:  Lupus       Date:  2006       Impact factor: 2.911

3.  Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.

Authors:  Przemyslaw J Kotyla; Bogna Sliwinska-Kotyla; Eugene J Kucharz
Journal:  J Rheumatol       Date:  2006-11       Impact factor: 4.666

4.  Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.

Authors:  Karen H Costenbader; Elizabeth W Karlson; Victoria Gall; Paola de Pablo; Axel Finckh; Marsha Lynch; Bonnie Bermas; Peter H Schur; Matthew H Liang
Journal:  Arthritis Rheum       Date:  2005-10-15

5.  Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study.

Authors:  M B Urowitz; D D Gladman; D Ibanez; Y Berliner
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

6.  A pravastatin dose-escalation study in systemic lupus erythematosus.

Authors:  Karen H Costenbader; Matthew H Liang; Lori B Chibnik; Juliet Aizer; Hannah Kwon; Victoria Gall; Elizabeth W Karlson
Journal:  Rheumatol Int       Date:  2007-04-03       Impact factor: 2.631

7.  Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.

Authors:  Tamar Aprahamian; Ramon Bonegio; Jennifer Rizzo; Harris Perlman; David J Lefer; Ian R Rifkin; Kenneth Walsh
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 8.  Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?

Authors:  Fatima Akdim; Sander I van Leuven; John J P Kastelein; Erik S G Stroes
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

9.  Natural history of hypercholesterolemia in systemic lupus erythematosus.

Authors:  I N Bruce; M B Urowitz; D D Gladman; D C Hallett
Journal:  J Rheumatol       Date:  1999-10       Impact factor: 4.666

10.  Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice.

Authors:  Sarah Lawman; Claudia Mauri; Elizabeth C Jury; H Terrence Cook; Michael R Ehrenstein
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422
View more
  10 in total

1.  Statin use in giant cell arteritis: a retrospective study.

Authors:  Jean Schmidt; Tanaz A Kermani; Francesco Muratore; Cynthia S Crowson; Eric L Matteson; Kenneth J Warrington
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

2.  Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.

Authors:  Ashley J Wilhelm; Amy S Major
Journal:  Int J Clin Rheumtol       Date:  2012-10-01

Review 3.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 4.  Immune modulatory effects of statins.

Authors:  Robert Zeiser
Journal:  Immunology       Date:  2018-02-20       Impact factor: 7.397

Review 5.  Dyslipidemia in systemic lupus erythematosus.

Authors:  Melinda Zsuzsanna Szabó; Peter Szodoray; Emese Kiss
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 6.  The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity.

Authors:  N S Wade; A S Major
Journal:  Thromb Haemost       Date:  2011-10-06       Impact factor: 5.249

7.  Expanding the therapeutic frontier in atherosclerosis.

Authors:  Amy S Major
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

8.  Effect of combined treatment with bisphosphonate and vitamin D on atherosclerosis in patients with systemic lupus erythematosus: a propensity score-based analysis.

Authors:  Kazumasa Ohmura; Masaru Kato; Toshiyuki Watanabe; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Yoichi M Ito; Norihiro Sato; Tatsuya Atsumi
Journal:  Arthritis Res Ther       Date:  2018-04-17       Impact factor: 5.156

Review 9.  The Shifting Landscape of Lupus Nephritis Management: A Review.

Authors:  Adegbenga A Bankole; Jane N Nwaonu
Journal:  Cureus       Date:  2022-01-05

Review 10.  Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.

Authors:  César Magro-Checa; Elisabeth J Zirkzee; Tom W Huizinga; Gerda M Steup-Beekman
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.